Longeveron (LGVN) Long-Term Deferred Tax (2021 - 2022)
Longeveron (LGVN) recorded quarterly Long-Term Deferred Tax of $11.9 million in Q4 2022, up 64.03% quarter-over-quarter from $7.3 million in Q4 2021, and up 64.03% on a YoY basis from $7.3 million in Q4 2021.
Longeveron (LGVN) Long-Term Deferred Tax (2021 - 2022) Analysis & Trends
Longeveron's Long-Term Deferred Tax history runs 2 years deep, the most recent figure standing at $11.9 million for Q4 2022.
- In Q4 2022, Long-Term Deferred Tax rose 64.03% year-over-year to $11.9 million; the TTM figure through Dec 2022 stood at $11.9 million (up 64.03% YoY), while the FY2022 annual figure was $11.9 million, up 64.03% from the prior year.
- Long-Term Deferred Tax was $11.9 million for Q4 2022 at Longeveron, up from $7.3 million in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $11.9 million in Q4 2022 to a low of $7.3 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 11.93 Mn |
| Dec 31, 2021 | 7.27 Mn |